Rice Hall James & Associates LLC Trims Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Rice Hall James & Associates LLC trimmed its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 7.1% in the 4th quarter, HoldingsChannel reports. The fund owned 678,541 shares of the biopharmaceutical company’s stock after selling 51,649 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Revance Therapeutics were worth $2,063,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RVNC. FORA Capital LLC purchased a new stake in Revance Therapeutics in the 3rd quarter worth approximately $54,000. Creative Planning bought a new position in Revance Therapeutics in the 3rd quarter worth approximately $56,000. Accredited Investors Inc. bought a new position in Revance Therapeutics in the 3rd quarter worth approximately $67,000. Dynamic Technology Lab Private Ltd bought a new position in Revance Therapeutics in the 3rd quarter worth approximately $88,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Revance Therapeutics by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 7,890 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RVNC has been the subject of several recent analyst reports. Barclays dropped their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. StockNews.com initiated coverage on Revance Therapeutics in a research note on Friday, February 14th. They issued a “hold” rating for the company. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Mizuho lowered their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

NASDAQ RVNC opened at $3.65 on Wednesday. The company has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $7.56. The stock has a 50 day moving average price of $3.37 and a 200-day moving average price of $4.58.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.